Biocryst Pharmaceuticals Inc (NASDAQ: BCRX)

$8.44 ▲ +0.03 (+0.30%)

As of Jun 08, 2026 04:00 PM

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic CIK: 0000882796

Market Cap 2.04 Bn

P/E -4.88

P/S 4.26

Div. Yield 0.00

ROIC (Qtr) 0.01

Total Debt (Qtr) 435.51 Mn

Revenue Growth (1y) (Qtr) 7.48

Add ratio to table...

About

BioCryst Pharmaceuticals Inc is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema and other rare diseases. The company's core activities include internal discovery and development of oral small-molecule and injectable protein therapeutics, strategic business development to acquire rare disease assets, and leveraging its commercial infrastructure to support product commercialization. BioCryst aims to optimize costs and allocate resources efficiently by concentrating on rare disease markets...

BioCryst Pharmaceuticals Inc is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema and other rare diseases. The company's core activities include internal discovery and development of oral small-molecule and injectable protein therapeutics, strategic business development to acquire rare disease assets, and leveraging its commercial infrastructure to support product commercialization. BioCryst aims to optimize costs and allocate resources efficiently by concentrating on rare disease markets to drive sustainable growth.

BioCryst generates revenue primarily through the commercialization of its approved products, including ORLADEYO for hereditary angioedema prophylaxis and RAPIVAB for acute uncomplicated influenza treatment. The company also earns income from licensing agreements, royalty payments, and milestone payments from collaborators such as Torii Pharmaceutical for ORLADEYO in Japan and Shionogi for peramivir in Japan and Taiwan. Revenue is derived from product sales in key markets including the United States, Europe, Japan, and other global territories where its therapies are approved and distributed.

The company operates through the following segments:

• ORLADEYO: This segment focuses on the development and commercialization of berotralstat, an oral, once-daily therapy for the prevention of hereditary angioedema attacks. ORLADEYO is available in capsule form for patients aged 12 years and older and as an oral pellet formulation for pediatric patients aged 2 to <12 years. The product is marketed under the ORLADEYO brand name in the United States and multiple global markets.

• Navenibart: This segment involves the development of STAR-0215, a monoclonal antibody plasma kallikrein inhibitor for hereditary angioedema prophylaxis. Navenibart is currently in Phase 3 clinical development and has received Fast Track and Orphan Drug designations from the FDA and Orphan Medicinal Product Designation from the European Commission. The goal is to deliver a best-in-class injectable therapy with a differentiated every 3- and 6-month administration schedule.

• BCX17725: This segment centers on a potent and selective investigational protein therapeutic KLK5 inhibitor for the treatment of Netherton syndrome. BCX17725 is designed to restore the normal skin barrier by replacing missing functions of the natural KLK5 inhibitor. The candidate is in Phase 1 clinical development in the United States and Australia and has received Fast Track designation from the FDA for Netherton syndrome.

• Avoralstat: This segment advances an investigational plasma kallikrein inhibitor for the treatment of diabetic macular edema via suprachoroidal delivery to the back of the eye. Avoralstat targets the kallikrein-bradykinin pathway to reduce vascular leakage and edema, aiming to lessen treatment burden. Clinical evaluation is ongoing in Australia, with plans to seek a strategic partner for development beyond Phase 1.

• STAR-0310: This segment develops a monoclonal antibody OX40 antagonist incorporating YTE half-life extension technology for atopic dermatitis. STAR-0310 is currently in a Phase 1a trial to assess safety, tolerability, pharmacokinetics, and immunogenicity in healthy subjects. The company plans to seek strategic alternatives for this asset following the acquisition of Astria Therapeutics.

• Peramivir Injection: This segment includes the commercialization of peramivir injection under the brand names RAPIVAB in the United States, Australia, and Canada; RAPIACTA in Japan and Taiwan; and PERAMIFLU in Korea. These products are intravenous neuraminidase inhibitors approved for the treatment of acute uncomplicated influenza.

BioCryst holds a competitive position in the rare disease therapeutics market, particularly in hereditary angioedema, where it faces competition from companies such as Takeda (Takhzyro), Pharming (Haegarda and Cinryze), and CSL Behring (Berinert). Its competitive advantages include a first-in-class oral prophylactic therapy for children aged 2 to <12 years with ORLADEYO pellets, a differentiated dosing schedule for navenibart, and a validated commercial infrastructure that enables efficient product launch and market penetration. The company’s structure-guided drug design capabilities and focus on underexplored biological targets further strengthen its pipeline differentiation.

BioCryst serves patients with rare diseases, including individuals with hereditary angioedema across all age groups, patients with Netherton syndrome, those suffering from diabetic macular edema, and individuals with atopic dermatitis. The company also supplies peramivir injection to government stockpiling programs via contracts with the U. S. Department of Health and Human Services for pandemic preparedness. Specific customer entities include specialty pharmacy providers in the United States, government health agencies such as the U. S. ASPR for RAPIVAB procurement, and international distributors like Neopharmed Gentili for European ORLADEYO commercialization prior to the asset sale.

Investment thesis

Bull case

BioCryst’s Orladeyo revenue hit $159.1 million in Q3 2025, a 37% jump year‑over‑year, and the company has raised its 2025 guidance to $590‑$600 million. The lift is driven by a 64‑prescriber expansion in the U.S. and a steady 82% paid‑rate, showing the drug’s pricing resilience even as new competitors appear. Management’s focus on prescriber engagement, especially in the pediatric niche, underlines a scalable growth engine that can push Orladeyo toward the projected $1 billion peak by 2029.
The recent FDA approval of an oral pellet formulation for children aged two to twelve opens a substantial underserved market that previously required IV or SC therapy. With an estimated 500 U.S. pediatric HAE patients, only 40% currently on prophylaxis, the pellet offers a convenient, child‑friendly option that can convert a large number of patients who are reluctant to use injections. The company’s intent to maintain pricing parity across dosage forms mitigates cannibalization concerns and preserves revenue per patient. Early market penetration is expected in April 2026, positioning BioCryst to capture a first‑mover advantage in a niche that is otherwise served by costly biologics.
The divestiture of the European business eliminated a $200 million term loan and removed a 10‑15 million dollar revenue stream, but it also unlocked $200 million in cash and a leaner balance sheet. The pro‑forma cash balance sits at $294 million, with zero term debt, allowing the company to fund research and acquisitions without incurring additional financing costs. Management projects $1 billion cash by 2029, underpinned by operating leverage that has more than doubled operating profit year‑over‑year. This financial cushion can absorb integration costs and support a strategic partnership with Blackstone that may bring up to $400 million in cash upon closing of the Astria acquisition.
The proposed acquisition of Astria Therapeutics introduces nivenabart, a long‑acting injectable for HAE, which aligns with BioCryst’s rare‑disease focus and expands its product line into a high‑barrier, high‑margin segment. Nivenabart’s low‑burden administration profile could complement Orladeyo’s oral therapy, allowing the company to cater to patients who prefer or require injection. The deal’s valuation of roughly $700 million is structured with earn‑outs and milestone payments, reducing upfront equity dilution and preserving cash flow. The anticipated close in Q1 2026 will immediately add a new revenue stream and diversify the company’s portfolio, potentially offsetting any future competitive pressure on Orladeyo.
BCX1775, a novel KLK5 inhibitor, has shown very favorable safety and epidermal penetration in phase I healthy volunteers, including robust tissue distribution at 12 mg/kg IV doses. The drug’s mechanism targets a critical enzyme overexpressed in Netherton syndrome, a rare pediatric skin disorder with no effective systemic therapy, positioning it as a breakthrough candidate in a high‑needs market. Early data indicate tolerability and potential dose‑response signals, which could accelerate the transition to phase II and, if successful, a fast‑track FDA pathway. The company’s plan to explore subcutaneous dosing further widens the administration options, enhancing patient convenience and market appeal.

BioCryst’s Orladeyo revenue hit $159.1 million in Q3 2025, a 37% jump year‑over‑year, and the company has raised its 2025 guidance to $590‑$600 million. The lift is driven by a 64‑prescriber expansion in the U.S. and a steady 82% paid‑rate, showing the drug’s pricing resilience even as new competitors appear. Management’s focus on prescriber engagement, especially in the pediatric niche, underlines a scalable growth engine that can push Orladeyo toward the projected $1 billion peak by 2029.
The recent FDA approval of an oral pellet formulation for children aged two to twelve opens a substantial underserved market that previously required IV or SC therapy. With an estimated 500 U.S. pediatric HAE patients, only 40% currently on prophylaxis, the pellet offers a convenient, child‑friendly option that can convert a large number of patients who are reluctant to use injections. The company’s intent to maintain pricing parity across dosage forms mitigates cannibalization concerns and preserves revenue per patient. Early market penetration is expected in April 2026, positioning BioCryst to capture a first‑mover advantage in a niche that is otherwise served by costly biologics.
The divestiture of the European business eliminated a $200 million term loan and removed a 10‑15 million dollar revenue stream, but it also unlocked $200 million in cash and a leaner balance sheet. The pro‑forma cash balance sits at $294 million, with zero term debt, allowing the company to fund research and acquisitions without incurring additional financing costs. Management projects $1 billion cash by 2029, underpinned by operating leverage that has more than doubled operating profit year‑over‑year. This financial cushion can absorb integration costs and support a strategic partnership with Blackstone that may bring up to $400 million in cash upon closing of the Astria acquisition.
The proposed acquisition of Astria Therapeutics introduces nivenabart, a long‑acting injectable for HAE, which aligns with BioCryst’s rare‑disease focus and expands its product line into a high‑barrier, high‑margin segment. Nivenabart’s low‑burden administration profile could complement Orladeyo’s oral therapy, allowing the company to cater to patients who prefer or require injection. The deal’s valuation of roughly $700 million is structured with earn‑outs and milestone payments, reducing upfront equity dilution and preserving cash flow. The anticipated close in Q1 2026 will immediately add a new revenue stream and diversify the company’s portfolio, potentially offsetting any future competitive pressure on Orladeyo.
BCX1775, a novel KLK5 inhibitor, has shown very favorable safety and epidermal penetration in phase I healthy volunteers, including robust tissue distribution at 12 mg/kg IV doses. The drug’s mechanism targets a critical enzyme overexpressed in Netherton syndrome, a rare pediatric skin disorder with no effective systemic therapy, positioning it as a breakthrough candidate in a high‑needs market. Early data indicate tolerability and potential dose‑response signals, which could accelerate the transition to phase II and, if successful, a fast‑track FDA pathway. The company’s plan to explore subcutaneous dosing further widens the administration options, enhancing patient convenience and market appeal.

Bear case

BioCryst’s revenue is heavily concentrated in a single product, Orladeyo, which faces increasing competition from injectable prophylactics that may erode market share. Management repeatedly assured that patient retention would remain unchanged, but the Q&A revealed anecdotal prescriber switching and potential cannibalization risk as new entrants offer alternative modalities. A shift in patient preference toward injectable therapies, especially among the 60% of prescribers who historically have not written Orladeyo, could materially compress volumes.
The company’s reliance on a 60% one‑year patient retention rate is a fragile metric in a rapidly evolving therapeutic landscape. While management cited steady retention, the data were presented without a detailed breakdown by prescriber type or disease severity, leaving uncertainty about whether retention will hold as competition intensifies or as payer coverage policies change. A decline in retention would directly translate into lost revenue and increased marketing costs to reacquire patients.
The Orladeyo pellet launch, although a strategic expansion, carries significant uncertainty regarding timing, pricing, and reimbursement. The company’s promise of pricing parity across formulations may be difficult to sustain if payer negotiations for the pellet are more complex or if the pellet’s cost of goods is higher. Delays or coverage denials could postpone revenue capture and erode the projected 2026 growth trajectory.
The proposed Astria acquisition, while offering a new product line, adds substantial debt and integration risk. The $700 million valuation may over‑value nivenabart if the market is slower to adopt injectable prophylactics or if reimbursement hurdles arise. Additionally, the acquisition introduces a non‑core asset that could distract from Orladeyo’s commercialization, potentially diluting focus and resource allocation.
BCX1775’s clinical data, though encouraging in healthy volunteers, remain preliminary and carry typical phase I uncertainties. The lack of efficacy data in patients, coupled with the extreme rarity of Netherton syndrome, limits the market size and increases the risk of a failed pivotal study. Regulatory approval for a skin‑penetrating inhibitor is also unprecedented, raising unknown safety and efficacy thresholds that could delay or derail the program.

BioCryst’s revenue is heavily concentrated in a single product, Orladeyo, which faces increasing competition from injectable prophylactics that may erode market share. Management repeatedly assured that patient retention would remain unchanged, but the Q&A revealed anecdotal prescriber switching and potential cannibalization risk as new entrants offer alternative modalities. A shift in patient preference toward injectable therapies, especially among the 60% of prescribers who historically have not written Orladeyo, could materially compress volumes.
The company’s reliance on a 60% one‑year patient retention rate is a fragile metric in a rapidly evolving therapeutic landscape. While management cited steady retention, the data were presented without a detailed breakdown by prescriber type or disease severity, leaving uncertainty about whether retention will hold as competition intensifies or as payer coverage policies change. A decline in retention would directly translate into lost revenue and increased marketing costs to reacquire patients.
The Orladeyo pellet launch, although a strategic expansion, carries significant uncertainty regarding timing, pricing, and reimbursement. The company’s promise of pricing parity across formulations may be difficult to sustain if payer negotiations for the pellet are more complex or if the pellet’s cost of goods is higher. Delays or coverage denials could postpone revenue capture and erode the projected 2026 growth trajectory.
The proposed Astria acquisition, while offering a new product line, adds substantial debt and integration risk. The $700 million valuation may over‑value nivenabart if the market is slower to adopt injectable prophylactics or if reimbursement hurdles arise. Additionally, the acquisition introduces a non‑core asset that could distract from Orladeyo’s commercialization, potentially diluting focus and resource allocation.
BCX1775’s clinical data, though encouraging in healthy volunteers, remain preliminary and carry typical phase I uncertainties. The lack of efficacy data in patients, coupled with the extreme rarity of Netherton syndrome, limits the market size and increases the risk of a failed pivotal study. Regulatory approval for a skin‑penetrating inhibitor is also unprecedented, raising unknown safety and efficacy thresholds that could delay or derail the program.

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer comparison

Companies in the Drug Manufacturers - Specialty & Generic

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	TEVA	Teva Pharmaceutical Industries Ltd	38.34 Bn	24.21	2.21	16.63 Bn
2	ZTS	Zoetis Inc.	33.27 Bn	13.05	3.50	9.05 Bn
3	UTHR	UNITED THERAPEUTICS Corp	23.75 Bn	18.65	7.49	-
4	ACB	Aurora Cannabis Inc	17.11 Bn	5.38	64.07	0.00 Bn
5	NBIX	Neurocrine Biosciences Inc	16.37 Bn	24.27	5.28	-
6	ELAN	Elanco Animal Health Inc	11.78 Bn	-47.34	2.41	3.99 Bn
7	ALKS	Alkermes plc.	7.05 Bn	45.64	5.84	1.51 Bn
8	LNTH	Lantheus Holdings, Inc.	6.49 Bn	23.75	4.20	0.57 Bn

Research Tools

Developers

Biocryst Pharmaceuticals Inc (NASDAQ: BCRX)

About

Investment thesis

Bull case

Bear case

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer comparison

Research Tools

Developers

Biocryst Pharmaceuticals Inc (NASDAQ: BCRX)

About

Investment thesis

Bull case

Bear case

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer comparison

Create an account

Sign In

Reset Password